310 related articles for article (PubMed ID: 8962235)
1. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
[No Abstract] [Full Text] [Related]
2. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
Bismuth H
Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
[No Abstract] [Full Text] [Related]
3. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
Jacob DA; Neumann UP; Bahra M; Langrehr JM; Neuhaus P
Transplant Proc; 2005 May; 37(4):1691-2. PubMed ID: 15919432
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
Sher LS; Cosenza CA; Petrovic LM; Rojter S; Hoffman A; Lopez RR; Meehan M; Pan SH; Vierling J; Makowka L
Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
[No Abstract] [Full Text] [Related]
5. FK506 for primary and rescue therapy following liver transplantation.
Platz KP; Mueller AR; Zytowski M; Lobeck H; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1409-10. PubMed ID: 9636570
[No Abstract] [Full Text] [Related]
6. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation.
Platz KP; Mueller AR; Neuhaus R; Keck HH; Lobeck H; Neuhaus P
Transplant Proc; 1997 Nov; 29(7):2872-4. PubMed ID: 9365598
[No Abstract] [Full Text] [Related]
7. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
Arnold JC; Theilmann L
Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
[No Abstract] [Full Text] [Related]
8. FK 506 induction and rescue therapy in pancreas transplant recipients.
Stratta RJ; Taylor RJ; Castaldo P; Sindhi R; Sudan D; Weide LG; Frisbie K; Cushing KA; Jerius J; Radio SJ
Transplant Proc; 1996 Apr; 28(2):991-2. PubMed ID: 8623492
[No Abstract] [Full Text] [Related]
9. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
Bechstein WO; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Ericzon BG; Bismuth H
Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
[No Abstract] [Full Text] [Related]
10. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection.
Platz KP; Mueller AR; Zytowski M; Bechstein WO; Blumhardt G; Lobeck H; Neuhaus P
Transplant Proc; 1995 Feb; 27(1):1111-3. PubMed ID: 7533357
[No Abstract] [Full Text] [Related]
11. Long-term follow-up in hepatitis C patients with respect to immunosuppression.
Mueller AR; Platz KP; Berg T; Fukomoto T; Guckelberger O; Neuhaus R; Bechstein WO; Hopf U; Lobeck H; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3241-2. PubMed ID: 8962255
[No Abstract] [Full Text] [Related]
12. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
[No Abstract] [Full Text] [Related]
13. Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin.
Cholongitas E; Shusang V; Germani G; Tsochatzis E; Raimondo ML; Marelli L; Senzolo M; Davidson BR; Patch D; Rolles K; Burroughs AK
Clin Transplant; 2011; 25(4):614-24. PubMed ID: 20718824
[TBL] [Abstract][Full Text] [Related]
14. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
[No Abstract] [Full Text] [Related]
15. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis.
Lemmens HP; Langrehr JM; Blumhardt G; Lohmann R; Knoop M; Verschl J; Schattenfroh N; Neuhaus R; Hopf U; Bechstein WO
Transplant Proc; 1994 Dec; 26(6):3622-3. PubMed ID: 7527983
[No Abstract] [Full Text] [Related]
16. Clinical use of FK 506 in liver transplantation.
Klintmalm GB
Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
[TBL] [Abstract][Full Text] [Related]
17. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
[No Abstract] [Full Text] [Related]
18. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
Mueller AR; Platz KP; Bechstein WO; Blumhardt G; Lobeck H; Hop U; Neuhaus P
Transplant Proc; 1994 Dec; 26(6):3637-9. PubMed ID: 7527984
[No Abstract] [Full Text] [Related]
19. Is the use of marginal liver grafts justified?
Mueller AR; Platz KP; Krause P; Steinmüller T; Glanemann M; Neumann U; Lobeck H; Neuhaus P
Transplant Proc; 1999; 31(1-2):401-2. PubMed ID: 10083160
[No Abstract] [Full Text] [Related]
20. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
[No Abstract] [Full Text] [Related]
[Next] [New Search]
